In this study of patients with type 2 diabetes, treatment with sitagliptin was associated with a significant decrease in serum ghrelin levels….

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced the FDA approved Jentadueto™ (linagliptin/metformin hydrochloride) tablets….

A new study links the diabetes drug metformin to fewer cases of pancreatic cancer — at least in women — but finds other diabetes medications are associated with a higher risk of the disease.…

In diabetes patients, the stroke-preventing benefits of bringing systolic blood pressure below 130 mmHg may be offset by an increased risk of cardiac events.…

Use of electronic health records shows promise for improving care and outcomes in patients with type 2 diabetes, but still has considerable room for improvement….

In a study of more than 4,000 black women in Los Angeles, those who lived in areas with higher levels of traffic-related air pollution were at increased risk of diabetes and hypertension….

In a once weekly injection of exenatide for Drug-Naive Patients with Type 2 Diabetes (DURATION-4) in a 26-week double-blind study they found that exenatide once weekly (EQW) was noninferior to metformin (MET) but not pioglitazone (PIO) and superior to sitagliptin (SITA) with regard to HbA1c reduction at 26 weeks….

Vivus Inc said the FDA has asked the company to remove a contraindication in the proposed label of its obesity drug Qnexa, a move that could help it reach a broader patient population.…

The study findings indicate that medical professionals with normal BMI more frequently reported discussing weight loss with patients than overweight or obese medical professionals….

Two new studies from a team of investigators suggest two possible predictors for the development of metabolic syndrome in children prescribed second-generation antipsychotics (SGAs)….